Mineralys Therapeutics, Inc. Form 4 Filings

Mineralys Therapeutics, Inc. (MLYS) director Brian Taylor Slingsby reported that Catalys Pacific Fund, LP sold 104,320 common shares on September 22, 2026, at a weighted-average price of $28.8085 per share. The sales occurred in multiple transactions at prices from $28.700 to $28.905, and the fund held 7,805,718 shares following the sale. Slingsby may be deemed to share voting and investment power over the fund’s shares but disclaims beneficial ownership except to the extent of his pecuniary interest. No Rule 10b5-1 plan is reported.

Mineralys Therapeutics, Inc. (MLYS) reported that Chief Commercial Officer Warren Eric exercised stock options for 7,438 shares of common stock on September 21, 2026 at an exercise price of $13.24 per share and sold the same 7,438 shares at a weighted-average price of $28.1172 per share. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Following the option exercise, Eric held 230,563 stock options directly, expiring on April 21, 2035, subject to the stated vesting schedule.

Mineralys Therapeutics, Inc. (MLYS) director Daphne Karydas reported an option exercise and share sale on September 15, 2026. She exercised stock options for 3,000 shares of common stock at an exercise price of $12.02 per share, leaving 35,000 options outstanding under that award. On the same date, she sold 3,000 common shares at $28.58 per share. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025, and the option is scheduled to vest in 36 monthly installments beginning October 13, 2023, with an expiration date of September 13, 2033.

Mineralys Therapeutics, Inc. (MLYS) reported that Chief Commercial Officer Eric Warren exercised stock options and sold the resulting shares on August 21, 2026. He exercised 7,437 stock options at an exercise price of $13.24 per share into 7,437 shares of common stock, then sold 7,437 shares at a weighted‑average price of $25.9767 per share in multiple trades. Following the option exercise, he held 238,001 stock options directly. These transactions were effected pursuant to a Rule 10b5‑1 stock selling plan adopted on March 27, 2026.

Mineralys Therapeutics, Inc. reported that Chief Medical Officer James J. Ferguson III received equity-based compensation on 2026-08-10. He was granted 102,400 shares of common stock in the form of Restricted Stock Units (RSUs), vesting in four equal annual installments starting on the first anniversary of the grant date. He also received a stock option for 135,000 shares of common stock at an exercise price of $27.38 per share, vesting 25% on the first anniversary and the remainder in 36 substantially equal monthly installments, and expiring on 2036-08-10. Following these awards, his reported direct holdings related to these grants are 102,400 common shares and options for 135,000 shares.

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised 2,170 stock options for Common Stock at an exercise price of $16.00 per share on August 10, 2026, then sold 2,170 Common shares at $27.09 per share. The option exercise and related sale were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. Following the transaction, he held 13,024 stock options directly.

Mineralys Therapeutics Chief Commercial Officer Eric Warren exercised 7,438 stock options for common shares at $13.24 per share and, on the same date, sold 7,438 shares at a weighted-average price of $26.8735 (within a $26.53–$27.09 range) under a Rule 10b5-1 plan adopted March 27, 2026. After the exercise, he continues to hold 245,438 stock options directly.

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised stock options for 416 shares of common stock at $15.4400 per share and on the same day sold 416 shares at $26.5300, all under a Rule 10b5-1 trading plan adopted on October 6, 2025. After the exercise, 3334 stock options from this grant remain outstanding, expiring on 2033-03-17.

Mineralys Therapeutics, Inc. director and Chief Executive Officer Jon Congleton reported an open-market sale of 10,700 shares of common stock on July 13, 2026 at a weighted-average price of $27.2375 per share. The transactions were effected under a Rule 10b5-1 trading plan adopted on January 28, 2025, and Congleton now holds 603,621 shares directly.

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman reported option exercises and stock sales. On July 13, 2026 he exercised options for 14,058 common shares at strike prices of $1.08, $10.20 and $14.25. He then sold a total of 20,407 shares in open-market transactions at weighted-average prices of $27.5798 and $26.6112, pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025. After these transactions, he owns 51,384 common shares directly.

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options and sold common shares in a coordinated transaction. He exercised 2,171 stock options at $16.00 per share, then sold 2,171 common shares at $30.30 per share under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he holds 57,733 common shares, including 638 shares from the 2023 Employee Stock Purchase Plan, and retains 15,194 stock options exercisable at $16.00 per share expiring on February 9, 2033.

Mineralys Therapeutics, Inc. director and Chief Executive Officer Jon Congleton reported selling a total of 75,000 shares of common stock in open-market transactions on June 30, 2026. The filing shows two sales: 58,000 shares at a weighted-average price of $25.9432 per share and 17,000 shares at a weighted-average price of $26.8174 per share.

According to the footnotes, these transactions were executed under a Rule 10b5-1 trading plan adopted on December 30, 2025, and each reported price reflects multiple trades within disclosed price ranges. The Form 4 indicates that Congleton continues to hold a substantial direct stake in Mineralys common stock following these sales.

Mineralys Therapeutics Chief Commercial Officer Eric Warren exercised stock options and sold shares in a planned transaction. He exercised options for 104,124 shares of common stock at $13.24 per share and sold 104,124 shares at a weighted-average price of $25.8953 per share.

These trades were carried out under a Rule 10b5-1 stock selling plan adopted on March 27, 2026, indicating they were pre-scheduled. Following the transactions, Warren directly owns 38,400 shares of Mineralys common stock.

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a mix of option exercises and share sales in mid-June. On June 15 and June 17, he sold a total of 14,474 shares of common stock in open-market transactions at weighted-average prices around $23.81 and $25.00.

To support these sales, he exercised stock options covering 8,126 shares at exercise prices of $10.20, $14.25 and $15.44. After the transactions, he directly holds 57,095 shares of common stock. The filing notes that the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025.

Mineralys Therapeutics director Daphne Karydas exercised stock options for 3,000 shares of common stock at $12.02 per share and sold 3,000 shares at $25.00 per share. After these transactions, she holds 6,200 shares directly. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom reported option exercises and related stock sales. On June 12, 2026, he exercised options for 6,349 shares of common stock at $1.08 per share and sold 6,349 shares in an open-market transaction at a weighted-average price of $23.9252 per share under a pre-arranged Rule 10b5-1 trading plan. On June 10, 2026, he exercised options for 2,170 shares at $16.00 per share and sold 2,170 shares at $25.00 per share. Following these transactions, Malcom directly holds 63,443 shares of Mineralys common stock.

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom reported a small, pre-planned stock transaction. He exercised stock options covering 417 shares of common stock at $15.44 per share and sold 417 common shares at $27.55 per share under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he directly holds 63,443 shares of common stock and 4,167 stock options, indicating this activity affected only a small portion of his overall position.

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a series of equity transactions in May. Over May 11–13, 2026, he sold a total of 22,575 shares of Mineralys common stock in open-market trades at weighted-average prices around the high-$20s per share.

On the same dates, he exercised stock options for 16,226 shares at strike prices ranging from $1.08 to $16.00 per share, converting option awards into common stock. After these transactions, he directly held 63,443 shares of common stock. The filing notes that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a small, pre-planned insider transaction. On April 17, 2026, he sold 416 shares of common stock in an open-market sale at $31.33 per share and exercised stock options for 416 shares at $15.44 per share. These trades were made under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following the sale, he directly owned 69,792 shares of common stock and held 4,584 stock options as reported in this filing.

Mineralys Therapeutics, Inc. Chief Medical Officer Rodman David Malcom reported option exercises and share sales in the company’s stock. On April 13, he exercised stock options covering a total of 14,058 shares of Common Stock at strike prices of $1.08, $10.20, and $14.25 per share. That same day, he conducted an open-market sale of 14,058 shares of Common Stock at a weighted-average price of $26.5391 per share. On April 15, he completed a second open-market sale of 6,348 shares at $27.66 per share under a Rule 10b5-1 trading plan. After these transactions, he directly holds 69,792 shares of Common Stock.

Mineralys Therapeutics, Inc. Chief Executive Officer Jon Congleton reported an open-market sale of 15,730 shares of common stock on April 13, 2026 at a weighted-average price of $26.8264 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.

Following this sale, Congleton directly holds 689,321 shares of Mineralys common stock, indicating that the transaction covers only a portion of his overall equity position. The shares were sold in multiple trades at prices ranging from $26.81 to $26.96.

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options for 2,170 shares of common stock at $16.00 per share and then sold 2,170 shares in an open-market transaction at $27.38 per share.

These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. Following the sale, he directly holds 76,140 shares of Mineralys Therapeutics common stock.

Mineralys Therapeutics, Inc. Chief Executive Officer Jon Congleton reported open-market sales of a total of 75,000 shares of the company’s Common Stock on March 31, 2026. The transactions were executed at weighted-average prices of $25.5006, $26.5385, and $27.0511 per share across multiple trades. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025. Following the transactions, Congleton directly holds 705,051 shares of Mineralys Therapeutics Common Stock.

Mineralys Therapeutics director Daphne Karydas reported an option exercise and share sale. She exercised stock options to acquire 3,000 shares of common stock at $12.02 per share, then sold 3,000 common shares in an open-market transaction at $25.00 per share.

After these transactions, she directly holds 6,200 shares of common stock and 41,000 stock options. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.

RA Capital–managed funds reported open-market purchases of Mineralys Therapeutics stock. On March 27, 2026, they bought 310,700 shares of common stock at a weighted average price of $23.67 per share. On March 30, 2026, they added 58,300 shares at a weighted average price of $24.16 per share.

Shares are held indirectly through RA Capital Healthcare Fund LP and RA Capital Nexus Fund III, L.P., with RA Capital Management, L.P. acting as investment manager. After these transactions, one fund held 5,825,521 shares as of March 30, 2026, while another related fund held 1,867,229 shares as of March 27, 2026.

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised stock options for 417 shares of common stock at $15.44 per share and on the same day sold 417 shares at $25.65 per share in an open-market trade. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. After these transactions, he directly owns 76,140 shares of Mineralys Therapeutics common stock, so the sale represents a small portion of his overall holdings.

Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales in Mineralys Therapeutics, Inc. common stock. On March 12–13, 2026, he exercised stock options for a total of 14,057 shares of common stock at exercise prices of $1.08, $10.20, and $14.25 per share. He then sold 20,406 shares in open-market transactions at weighted-average prices between approximately $25.77 and $27.92, executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he directly holds 76,140 shares of Mineralys Therapeutics common stock.

Mineralys Therapeutics Chief Medical Officer David Malcom Rodman exercised stock options for 2,171 shares of common stock at $16.00 per share and on the same day sold 2,171 shares at $26.84 per share in an open-market transaction. The filing describes these moves as an exercise or conversion of derivative securities followed by a sale. After the transactions, he directly owned 82,489 shares of common stock and held stock options covering 23,876 shares. The company notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were scheduled in advance.

RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in this Form 4 filing.

Mineralys Therapeutics, Inc. reported an insider equity award arrangement involving RA Capital–affiliated entities. A partner of RA Capital Management serving on Mineralys’ board received 6,200 restricted stock units and a stock option for 8,300 shares of common stock, both granted for no additional cash consideration.

The RSUs vest in one annual installment after the grant date, while the option vests in 12 substantially equal monthly installments. According to the disclosures, these awards are held for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund III, with any shares or cash received offsetting advisory fees owed to RA Capital Management. The reporting persons disclaim beneficial ownership of the option and underlying common stock except to the extent of their pecuniary interest. Indirect holdings also include 5,456,521 shares of common stock held directly by the fund and 1,867,229 shares held directly by Nexus Fund III.

Mineralys Therapeutics, Inc. reported that Chief Executive Officer Jon Congleton received new equity-based compensation on February 19, 2026. He was granted 187,900 stock options, which vest in equal monthly installments over four years, with 1/48th of the total vesting each month after the grant date.

Congleton also acquired 140,900 shares of common stock through a grant of restricted stock units (RSUs) for no additional cash consideration. Each RSU represents one share of common stock and vests in four annual installments of 25% each on the yearly anniversaries of the grant date, bringing his direct common stock holdings to 780,051 shares.

SBLENDORIO GLENN reported acquisition or exercise transactions in this Form 4 filing.

Mineralys Therapeutics director Glenn Sblendorio reported equity awards consisting of 8,300 stock options and 6,200 shares of common stock on February 19, 2026. The common stock reflects restricted stock units granted for no cash consideration, vesting in one annual installment, while the options vest in 12 substantially equal monthly installments following the grant date.

Gold Alexander M reported acquisition or exercise transactions in this Form 4 filing.

Mineralys Therapeutics, Inc. director Alexander M. Gold reported awards of equity on February 19, 2026. He received a stock option covering 8,300 shares at a price of $0.0000 per share, and his option holdings after the transaction were 8,300 shares. He was also granted 6,200 shares of common stock, with total common stock holdings after the award of 6,200 shares.

According to the footnotes, the common stock reflects restricted stock units (RSUs) granted for no additional cash consideration, each representing one share of common stock that vests in one annual installment following the grant date. The stock option vests in 12 substantially equal monthly installments following the date of grant.

Karydas Daphne reported acquisition or exercise transactions in this Form 4 filing.

Mineralys Therapeutics, Inc. director Daphne Karydas reported equity awards consisting of stock options and restricted stock units. She was granted stock options for 8,300 shares at a price of $0.00 per share, vesting in 12 substantially equal monthly installments following the grant date.

She also received 6,200 restricted stock units (RSUs)

Mineralys Therapeutics, Inc. director and more than 10% owner Brian Taylor Slingsby reported equity awards and related transfers on February 19, 2026. He received 8,300 stock options and 6,200 restricted stock units (RSUs) at an exercise/award price of $0.00 per share.

The RSUs give a contingent right to one common share each and vest in one annual installment after the grant date, while the stock options vest in 12 substantially equal monthly installments following the grant date. Certain options and RSUs were transferred under an option transfer agreement to Catalys Pacific Fund, LP, and some securities are held of record by that fund.

Catalys Pacific Fund, LP’s general partner is Catalys Pacific Fund GP, LP, whose general partner is Catalys Pacific, LLC. These entities and Brian Taylor Slingsby may be deemed to share voting and investment power over shares held by the fund, but each disclaims beneficial ownership except to the extent of any pecuniary interest.

Mineralys Therapeutics director and 10% owner Srinivas Akkaraju reported equity grants. On February 19, 2026, he acquired a stock option covering 8,300 shares at $0.00 per share and 6,200 shares of common stock granted for no cash consideration as restricted stock units.

The footnotes state each RSU represents one share of common stock that vests in one annual installment following the grant date, while the stock option vests in 12 substantially equal monthly installments after grant. The filing also reports indirect ownership of 5,871,018 common shares held through Samsara Opportunity Fund, L.P. and Samsara BioCapital L.P., over which Dr. Akkaraju has voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.

DiRocco Derek reported acquisition or exercise transactions in this Form 4 filing.

Mineralys Therapeutics, Inc. director Derek DiRocco reported awards linked to company equity that he holds for the benefit of RA Capital-managed funds. He was granted stock options for 8,300 shares and restricted stock units representing 6,200 shares of common stock, each at a price of $0.0000 per share.

According to the disclosure, these stock options vest in 12 substantially equal monthly installments after the grant date, while the restricted stock units vest in one annual installment after the grant date. Under an arrangement with RA Capital Management, L.P., any net cash or stock from these awards is turned over to RA Capital Healthcare Fund, L.P. and RA Capital Nexus III Fund, L.P., and DiRocco disclaims beneficial ownership of the awards and underlying common stock.

Mineralys Therapeutics reported that Chief Medical Officer David Malcom acquired new equity awards on February 19, 2026. He received 51,300 stock options with an exercise price of $0.00 per share and now holds 51,300 options in total. He also received 38,400 shares of common stock for no cash consideration, increasing his direct common share holdings to 82,489 shares. The 38,400-share grant is in the form of restricted stock units that vest in four equal annual installments on each one-year anniversary of the grant date. The stock options vest separately in 48 equal monthly installments over four years following the grant date.

Levy Adam Scott reported acquisition or exercise transactions in this Form 4 filing.

Mineralys Therapeutics CFO Adam Scott Levy reported equity awards consisting of stock options and restricted stock units. He was granted 53,300 stock options and RSUs covering 39,900 shares of common stock, each at a reported price of $0.00 per share as compensation rather than open-market purchases.

The RSUs were granted for no additional cash consideration and represent contingent rights to receive common stock upon vesting. They vest in four equal annual installments on each one-year anniversary of the grant date. The stock options vest separately in 48 equal monthly installments over four years, with 1/48th of the option vesting each month after the grant date.

Mineralys Therapeutics, Inc. Chief Medical Officer Rodman David Malcom reported option and stock transactions in company shares. On February 17, 2026, he exercised a stock option for 417 shares of common stock at $15.44 per share and then sold 417 shares at $27.59 per share.

After these transactions, he directly owned 44,089 shares of common stock and 5,417 stock options. The filing states the trades were carried out under a Rule 10b5-1 trading plan adopted on October 6, 2025, indicating they were pre-arranged rather than discretionary trades.

Mineralys Therapeutics (MLYS) Chief Medical Officer Rodman David Malcom reported option exercises and share sales in mid-February 2026. On February 12 and 13, 2026, he exercised stock options for 6,349, 3,541 and 4,166 common shares at exercise prices of $1.08, $10.20 and $14.25 per share.

He then sold portions of the resulting common stock in open‑market transactions at weighted‑average prices of $28.9353, $29.6387, $27.33 and $27.5835, all under a Rule 10b5‑1 trading plan adopted on October 6, 2025. After these transactions, he directly owned 44,089 shares of common stock, along with multiple remaining stock option positions.

Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales. On February 9, 2026, he exercised stock options covering 2,171 shares of common stock at $16 per share and received the underlying common shares.

On the same date, he sold 2,171 shares of Mineralys Therapeutics common stock in an open-market transaction at an average price of $30.21 per share, leaving him with 50,437 common shares held directly and 26,047 stock options outstanding. The filing states these trades were made under a Rule 10b5-1 trading plan adopted on October 6, 2025.

Mineralys Therapeutics, Inc. insider Rodman David Malcom, the Chief Medical Officer, reported routine equity transactions in company stock. On January 20, 2026, he exercised a stock option for 416 shares of common stock at an exercise price of $15.44 per share and then sold 416 shares of common stock at a price of $32.1 per share.

After these trades, he beneficially owned 50,437 shares of common stock directly and 5,834 stock options directly. The filing notes these transactions were carried out under a Rule 10b5-1 trading plan adopted on October 6, 2025, which is a pre-arranged plan designed to allow insiders to sell shares over time in a structured manner.

Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reported option exercises and share sales in company stock. On January 13, 2026, he exercised stock options for 3,542 shares at $10.20 per share and 4,167 shares at $14.25 per share, receiving the same number of common shares. That day he sold 7,709 shares at $32.75 per share, followed by a sale of 11,367 shares at a weighted-average price of $32.6071 on January 14, 2026.

The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on October 6, 2025. After the reported trades, Malcom beneficially owned 50,437 shares of common stock, plus stock options for 131,042 shares and 104,167 shares that vest over time according to their grant terms.

Mineralys Therapeutics, Inc. insider filing shows planned stock sales by its Chief Executive Officer, Jon Congleton. On 01/12/2026, he sold 9,119 shares of common stock at a weighted-average price of $32.2083 and 7,117 shares at a weighted-average price of $33.1505, both coded as open-market sales.

The transactions were executed under a Rule 10b5-1 trading plan adopted on January 28, 2025, which is designed to pre-arrange trades. After these sales, Congleton directly beneficially owned 639,151 shares of Mineralys common stock.

Mineralys Therapeutics, Inc. reported an insider share sale by its CFO and Secretary, Adam Scott Levy. On 01/12/2026, he sold 10,758 shares of common stock in an open-market transaction at a weighted-average price of $32.1364 per share, under transaction code "S" for a sale. After this trade, he directly owned 8,638 shares of Mineralys common stock.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Levy adopted on November 14, 2023. The filing notes that the reported price is an average and that the shares were sold in multiple trades at prices ranging from $31.90 to $32.37, with detailed trade breakdowns available on request.

Mineralys Therapeutics Chief Medical Officer trades shares under a pre-set plan. Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics, reported exercising stock options for 2,170 shares of common stock on January 9, 2026 at an exercise price of $16.00 per share and for 6,348 shares on January 12, 2026 at an exercise price of $1.08 per share.

On each date, he then sold the same number of common shares, with 2,170 shares sold at $33.27 and 6,348 shares sold at a weighted-average price of $32.3162, in multiple trades between $32.01 and $32.93. After these transactions, he directly beneficially owned 61,804 shares of common stock, along with stock options covering 28,218 and 38,092 shares from two grants. All trades were executed pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

Mineralys Therapeutics Chief Medical Officer Rodman David Malcom reportedmultiple stock option exercises and related share sales in early January 2026. On January 2, 2026, he exercised options for 10,053, 3,629, 9,347, 20,168 and 24,193 shares of common stock at exercise prices of $1.08, $15.44, $10.20, $16.00 and $14.25, respectively, then sold 70,037 shares at a weighted-average price of $35.8656.

On January 5, 2026, he exercised additional options for 28,038, 10,121, 26,069, 53,630 and 67,473 shares at the same exercise prices, and sold 139,245 shares at a weighted-average price of $34.8275 and 53,470 shares at a weighted-average price of $35.5256. Following the last reported transaction, he directly owned 61,804 common shares, which includes 680 shares purchased under the 2023 Employee Stock Purchase Plan that were not previously reported. All transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025.

Mineralys Therapeutics (MLYS) reported that its Chief Executive Officer and director exercised stock options for 24,082 shares of common stock on 11/21/2025 at an exercise price of $0.54 per share.

Following this transaction, the CEO directly holds 655,387 shares of Mineralys common stock. The filing also clarifies that the option’s exercise price was previously shown as $0.53 per share due to a rounding error in an earlier Form 3, and notes that the option vested 25% on March 12, 2022, with the remainder vesting in 36 substantially equal monthly installments.

Mineralys Therapeutics, Inc. (MLYS) reported an insider transaction by a major shareholder group associated with Catalys Pacific. On 11/20/2025, an indirect holder reported the sale of 1,000,000 shares of Mineralys common stock at $43.35 per share, coded as an "S" transaction, which indicates a sale.

After this transaction, the reporting entities collectively reported 7,903,838 shares of Mineralys common stock beneficially owned on an indirect basis. The filing identifies the reporting persons as including a director and a 10% owner, with the shares held of record by Catalys Pacific Fund, LP and controlled through its general partner structure. The related entities and Brian Taylor Slingsby state that they may be deemed to have voting and investment power over these shares but disclaim beneficial ownership except to the extent of any pecuniary interest.